XML 53 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1

Revenues (Tables)

12 Months Ended

Dec. 31, 2023

Revenues [Abstract]

Schedule of net product revenues by product

The Company’s net product revenues consisted of the following for the years ended December 31:

						2023						2022
Products:
Kristalose						$	15,981,850					$	15,205,155
Vibativ						8,812,692						7,487,462
Sancuso						8,096,788						13,205,603
Caldolor						4,333,923						4,827,200
Acetadote						458,759						501,040
Omeclamox-Pak						20,030						29,145
Vaprisol						151,336						(447,697)
RediTrex						(341,886)						(126,726)
Total net product revenues						$	37,513,492					$	40,681,182

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenuesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration